Administration or delivery of a drug or vaccine through the nose, typically via a spray or drops that are absorbed by the nasal tissues. For investors, intranasal products can matter because they often offer easier, needle-free use, faster onset of effect, and potential cost or compliance advantages that can widen a product’s market and affect regulatory review, manufacturing complexity, and commercial prospects — similar to how a convenient app can outsell a clunky desktop program.
neurocircuitrymedical
Neurocircuitry is the network of connected brain cells and pathways that carry signals and control thoughts, emotions and bodily functions — like the wiring in an electrical system that routes power to different rooms. Investors care because many drugs, medical devices and diagnostics aim to change or monitor these networks; evidence that a treatment safely and predictably affects neurocircuitry can drive regulatory approval, market size and company value.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company will participate in the Jefferies 2026 Global Healthcare conference being held June 2-4, 2026, in New York City.
The Company will host one-on-one meetings with institutional investors during the conference. Investors interested in scheduling a meeting with Vistagen are encouraged to contact their Jefferies representative.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of rapid-onset neurocircuitry-focused intranasal product candidates called pherines. Vistagen’s pherine product candidates are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options, if successfully developed and approved. Vistagen’s most advanced intranasal pherine product candidates are fasedienol in U.S. Phase 3 development for the acute treatment of social anxiety disorder, itruvone for treatment of major depressive disorder, and refisolone for treatment of vasomotor symptoms (hot flashes) due to menopause. Connect at www.Vistagen.com.
